Strand Life Sciences, Bengaluru-based subsidiary of Reliance Industries Limited, on Tuesday (July 7, 2026) announced the grant of an Indian patent covering its integrated platform for early cancer detection using cell-free DNA (cfDNA) analysis.

According to an official communique, the patented platform brings together high-quality sequencing, rigorous quality control, biologically informed methylation and fragmentomic feature extraction, and machine learning to enable cancer detection and tissue-of-origin prediction from just a blood sample.

The patent covers a cell-free DNA analysis platform that enables early cancer detection from a blood test. Widespread methylation pattern changes across the genome are a hallmark of cancer. A key innovation in the patent, among others, is obtaining these methylation patterns using genome sequencing with minimal loss or failure, thus enabling sensitive early cancer detection, as per the company.

More than 1.5 million new cancer cases are estimated to occur annually, and unfortunately a large number of patients are still diagnosed at advanced stages, when treatment options are limited and outcomes are significantly poorer. Early detection has the potential to shift diagnoses to earlier stages. With decreasing costs of sequencing, the patented platform can potentially enable early detection at scale without expanding local infrastructure, the firm claimed.

“This patent reflects our commitment to developing scientifically rigorous, AI-enabled liquid biopsy technologies that can help detect cancer earlier from a simple blood sample. We believe this innovation represents an important step towards making precision cancer screening more accurate, scalable, and accessible,” said Ramesh Hariharan, CEO, Strand Life Sciences.